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We identified subsets of neurons in the brain that co-
express the dopamine receptor subtype-2 (DRD2)
and the ghrelin receptor (GHSR1a). Combination of
FRET confocal microscopy and Tr-FRET established
the presence of GHSR1a:DRD2 heteromers in hypo-
thalamic neurons. To interrogate function, mice were
treated with the selective DRD2 agonist cabergoline,
which produced anorexia in wild-type and ghrelin/
mice; intriguingly, ghsr/mice were refractory illus-
trating dependence on GHSR1a, but not ghrelin.
Elucidation of mechanism showed that formation of
GHSR1a:DRD2 heteromers allosterically modifies
canonical DRD2 dopamine signaling resulting in
Gbg subunit-dependent mobilization of [Ca2+]i inde-
pendent of GHSR1a basal activity. By targeting
the interaction between GHSR1a and DRD2 in
wild-type mice with a highly selective GHSR1a
antagonist (JMV2959) cabergoline-induced anorexia
was blocked. Inhibiting dopamine signaling in
subsets of neurons with a GHSR1a antagonist has
profound therapeutic implications by providing
enhanced selectivity because neurons expressing
DRD2 alone would be unaffected.
INTRODUCTION
The growth hormone secretagogue receptor GHSR1a was iden-
tified as an orphan G protein-coupled receptor (GPCR) by
expression cloning with a small molecule, MK-0677, that rejuve-
nates the GH axis in elderly subjects (Howard et al., 1996; Smith
et al., 1997). In situ hybridization and RNase protection assays in
rat and human brain illustrated expression in multiple hypotha-
lamic nuclei, in the dentate gyrus and CA2 and CA3 regions of
the hippocampal formation, as well as the substantia nigra,
ventral tegmental area, and dorsal and median raphe nuclei
(Guan et al., 1997). Subsequently, GHSR1a was deorphanized
by the discovery of ghrelin produced in the stomach that
enhances GH release and appetite (Dixit et al., 2007; Kojima
et al., 1999; Sun et al., 2006; Wren et al., 2001). Upon activation,
GHSR1a transduces its signal through Gaq/11, phospholipase C,inositol phosphate, and mobilization of Ca2+ from intracellular
stores (Smith et al., 1997).
Employing Ghsr-IRES-tauGFP knockin mice, we showed that
DRD1 is expressed in discrete sets of neurons in the brain that
also express GHSR1a (Jiang et al., 2006), and now show subsets
coexpressing GHSR1a and DRD2. We speculated that receptor
coexpression in the same neurons can led to interactions
between GHSR1a and DRD2 by modifying dopamine signaling
and translate it into discrete behavioral phenotypes. Paradoxi-
cally, despite the broad distribution of GHSR1a in the brain,
with the exception of extremely low levels measured in the
arcuate nucleus, endogenous ghrelin is undetectable (Cowley
et al., 2003; Grouselle et al., 2008). Resolution of this paradox
led to the experiments described herein and we provide
evidence for the role of unliganded GHSR1a (apo-GHSR1a) in
neurons via heteromerization with DRD2.
DRD2 is a member of GPCR A family; canonically DRD2 trans-
mits dopamine signal through Gai/o coupling, which results in in-
hibiting activity of adenylate cyclase and decreasing cAMP level
(Missale et al., 1998). Dopamine signaling through DRD2 has
been shown to regulate food intake (Fetissov et al., 2002; John-
son and Kenny, 2010; Palmiter, 2007; Pijl, 2003; Volkow et al.,
2011). Hypothalamus is a key center in homeostatic food regula-
tion and it has been shown that hypothalamic dopamine
signaling is important for basal regulation of food intake by influ-
encing feeding frequency and volume (Meguid et al., 2000). In
support of a role for DRD2 signaling in the regulation of feeding
behavior, pharmacologically increasing dopamine in the lateral
hypothalamus (LHA) induces anorexia and injection of a DRD2
antagonist into the LHA increases food intake (Vucetic and
Reyes, 2010).
Here, we examined whether coexpression of GHSR1a and
DRD2 in the same neuron leads to formation of heteromers
that exhibit unique pharmacological properties, or if crosstalk
between GHSR1a and DRD2 occurs independent of heterodi-
merization, as reported for other Gaq- and Gai-coupled receptor
pairs (Rives et al., 2009). We present evidence that in the
absence of ghrelin interactions between GHSR1a and DRD2
alters canonical DRD2 signal transduction resulting in dopa-
mine-induced [Ca2+]i mobilization. Based on results from a series
of in vitro experiments, we conclude that the mechanism is not
explained by receptor crosstalk, but by allosteric interaction
between apo-GHSR1a and DRD2.
Illustrating thephysiological relevance of our findings,weshow
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Figure 1. GHSR1a and DRD2 mRNA and
Protein Expression in Mouse Brain
(A) GHSR1a and DRD2 mRNA expression in
mouse striatum, hippocampus, and hypothal-
amus. No PCR products are detected in controls
containing no RT; the housekeeping gapdh was
used as a negative control. The sizes of PCR
products are: ghsr1a, 190 bp; drd2, 286 bp; and
gapdh, 428 bp.
(B) Identification of neurons coexpressing
GHSR1a and DRD2 inmouse brain. Brain sections
from ghsr-IRES-tauGFP mice were stained with
mouse DRD2 antibody and secondary Alexa647
(red); GHSR1a expressing neurons were localized
by detecting GFP (green). To amplify GFP signal,
sections were stained with GFP antibody and
secondary Alexa488. Coexpression of GHSR1a
and DRD2 is shown in overlay pictures with yellow
arrows indicating individual neurons coexpressing
GHSR1a and DRD2. Nuclei were stained with
DAPI (blue). In striatum, box represents the area
with higher magnification.
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Heteromers of GHSR1a and DRD2 Relevant in Feedingmice that the anorexigenic property of a DRD2 agonist is
dependent upon interactions with GHSR1a, but not ghrelin.
Furthermore, the demonstration that a highly selective GHSR1a
antagonist inhibits DRD2 agonist signaling in vitro and in vivo
supports our hypothesis that apo-GHSR1a is an allostericmodu-
lator of dopamine-DRD2 signaling. Most importantly, we also
show that GHSR1a:DRD2 heteromers exist naturally in native
hypothalamic neurons that regulate appetite.
This discovery is of fundamental importance toward under-
standing neuronal signaling because of a popular belief that
with the exception of GABAB receptors, where two dissimilar
subunits are required for agonist-induced signal transduction
in vivo (Jones et al., 1998), GPCR heteromers are in vitro artifacts
and physiologically irrelevant. Our findings have important
therapeutic implications because extensive resources have
been invested in developing GHSR1a antagonists as antiobesity
agents. Polymorphisms in DRD2 impair DRD2 signaling and are
associated with obesity in humans (Epstein et al., 2007). Placing
our findings in this context, we would predict that GHSR1a
antagonists might exacerbate rather than prevent obesity.
Indeed, a recent report concluded that the lack of efficacy of
GHSR1a antagonists in the clinic was a poor understanding
of the complexity of GHSR1a signaling in vivo (Costantini
et al., 2011).
RESULTS
Identification of Neurons Coexpressing ghsr1a and drd2
in Mouse Brain
To measure the relative expression of ghsr1a and drd2 mRNA
was isolated from different regions of the mouse brain. RT-
PCR shows ghsr1a expression is most abundant in hypothal-
amus compared to striatum and hippocampus and that drd2
is expressed mainly in the striatum with lesser amounts in the318 Neuron 73, 317–332, January 26, 2012 ª2012 Elsevier Inc.hypothalamus (Figure 1A). Immunofluorescence on brain
slices from Ghsr-IRES-tauGFP mice (Jiang et al., 2006) show
colocalization of DRD2 and GFP in subsets of neurons with
the most abundant coexpression in the hypothalamus (Fig-
ure 1B). The specificity of the DRD2 monoclonal antibody used
for immunofluorescence studies was rigorously tested (Figures
S1A–S1D available online). Importantly, DRD2 immunofluores-
cence was observed in brain slices from drd2+/+, but not drd2/
mice.
Quinpirole Induces Ca2+ Transients in Neuronal Cells
Coexpressing GHSR1a and DRD2
To investigate whether neuronal cells that coexpress GHSR1a
and DRD2 are characterized by modification of signal transduc-
tion, we selected the SH-SY5Y neuroblastoma cell line that
expresses DRD2 endogenously and generated SH-SY5Y cells
that stably expressGHSR1a (SH-GHSR1a). In SH-SY5Y parental
cells, DRD2 activation by the selective DRD2 agonist, quinpirole,
causes coupling to Gai without inducing release of intracellular
Ca2+, whereas quinpirole treatment of SH-GHSR1a cells
produces dose dependent rapid transient Ca2+ signals reaching
a maximum by 20 s (Figures 2A and 2B EC50 = 32.76 ± 3.4 nM).
Attenuation of the Ca2+ signal by the DRD2 antagonist raclopride
confirms DRD2 specificity (Figure 2C) and attenuation by the
GHSR1a antagonist/inverse agonist L-765,867, Subst P deriva-
tive (Holst et al., 2004; Smith et al., 1996).
Since GHSR1a and DRD2 colocalize in the hypothalamus
(Figure 1B), we prepared primary cultures of hypothalamic
neurons. Treatment of the cultured neurons induces rapid Ca2+
transients (Figure 2D, upper panel). After washing to remove
quinporole, ghrelin treatment produces an immediate Ca2+
response (Figure 2D, lower panel). These results are consistent
with coexpression of GHSR1a and DRD2 in hypothalamic
neurons.
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Figure 2. Apo-GHSR1a Modifies DRD2
Signaling Causing Quinpirole to Induce
Mobilization of [Ca2+]i in Neuronal Cells
(A) SH-GHSR1a (upper panel) or parental SH-
SY5Y (lower panel) neuronal cells transfected with
SNAP-DRD2 were loaded with Fluo-4. Changes in
[Ca2+] (shown in pseudocolor) were imaged after
quinpirole (10 mM) treatment. SNAP-DRD2 ex-
pressing cells (yellow arrows) were visualized by
labeling with red-fluorophore (BG-647, 2 mM).
Overlay pictures represent the DRD2 expressing
cells (red) loaded with Fluo-4 (green). Graphical
representation of changes in [Ca2+] over time
after quinpirole treatment (lower panel). Cells
coexpressing GHSR1a+DRD2 (SH-GHSR1a
transfected with SNAP-DRD2) show rapid Ca2+
transients; however, cells expressing only DRD2
SH-SY5Y transfected with SNAP-DRD2) show no
increase in [Ca2+].
(B) Dose dependence of quinpirole-stimulated
[Ca2+]i mobilization in SH-GHSR1a cells trans-
fected with DRD2.
(C) Quinpirole-induced increase in [Ca2+]i mobili-
zation is abolished by treatment with GHSR1a and
DRD2 antagonists. Pretreatment of SH-GHSR1a
cells transfected with DRD2 with raclopride or
substance P derivative for 5 min attenuates
quinpirole (10 mM)-induced Ca2+ signals. Data
represent the mean ± SEM for three independent
experiments with responses from five to ten
cells analyzed for each experiment. **p < 0.01,
***p < 0.001 versus untreated control.
(D) Primary neurons isolated from hypothalamus
were loaded with Fluo-4. [Ca2+]i level changes
(shown in pseudocolor) were imaged after quin-
pirole addition (10 mM, upper panels). After
washing, the same cells respond to ghrelin
(100 nM) treatment by increasing [Ca2+]i level
(lower panels). Scale bar represents 20 mm.
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and DRD2
To study GHSR1a and DRD2 interactions in a system where we
could control the relative concentrations of GHSR1a and DRD2,
we performed Ca2+ mobilization assays in HEK293 cells stably
expressing the bioluminescent calcium sensor aequorin (Button
and Brownstein, 1993). When DRD2 is expressed alone dopa-Neuron 73, 317–332,mine does not induce Ca2+ mobilization,
but when GHSR1a is coexpressed dopa-
mine induces dose-dependent rapid
Ca2+ transients with a maximal response
at 15–20 s (Figures 3A and 3B, EC50 =
41.88 ± 1.12 nM). To determine GHSR1a
specificity, the closely related motilin
receptor that also couples to Gaq/11
(Feighner et al., 1999) was coexpressed
with DRD2; in this context, dopamine
treatment does not induce a Ca2+
response (Figure 3B). As an additional
specificity control GHSR1a was coex-
pressed with the Gai/o-coupled cannabi-noid receptor type 1 (CB1R) instead of DRD2; treatment with
a CB1 agonist did not induce Ca2+ mobilization (Figure 3B). We
next tested for dopamine receptor agonist specificity. The
DRD2 selective agonist quinpirole dose-dependently increases
[Ca2+]i in cells coexpressing GHSR1a and DRD2, but not in cells
expressing either GHSR1a or DRD2 alone (Figure 3C). To deter-
mine DRD2 agonist specificity, cells coexpressing GHSR1a andJanuary 26, 2012 ª2012 Elsevier Inc. 319
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Figure 3. Functional Interactions between GHSR1a and DRD2 and Involvement of Gbg Subunits in Dopamine-Induced Ca2+ Mobilization in
Aequorin-HEK293 Cells
(A) Activation of transfected aequorin-HEK293 cells with dopamine (10 mM) produces rapid Ca2+ transients in cells coexpressing GHSR1a+DRD2 (-) but not in
cells expressing GHSR1a (:) or DRD2 (B) alone.
(B) Dose-dependent Ca2+ response to dopamine treatment in cells coexpressing GHSR1a+DRD2 (-). Dose-dependent Ca2+ responses to dopamine are not
observed in cells coexpressing motilin receptor + DRD2 (d), DRD2 alone (;) or in the presence of CB1R agonist (WIN-55212-2) in cells coexpressing
GHSR1a+CB1R (:).
(C) Specificity of agonist-induced Ca2+ response. Quinpirole dose-dependently increases [Ca2+] in cells coexpressing GHSR1a+ DRD2 (:) but not in cells
expressing GHSR1a (-) or DRD2 (A) alone.
(D) In cells coexpressingGHSR1a+DRD2, dopamine-induced Ca2+ signaling is inhibited by raclopride (-) but not by the D1R-specific antagonist SCH 23390 (:).
(E) Pretreatment of cells with pertussis toxin (PTX, 0.25 mg/ml) inhibits dopamine-induced (100 nM) Ca2+ release in cells coexpressing GHSR1a + DRD2.
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Heteromers of GHSR1a and DRD2 Relevant in FeedingDRD2 were treated with DRD2 selective antagonist raclopride
or the DRD1 antagonist SCH23390. The former inhibited
dopamine-induced Ca2+ signaling, but the latter was ineffective
(Figure 3D), illustrating DRD2 selectivity.
GHSR1a Modification of DRD2 Signal Transduction via
Activation of Gbg Subunits
To probe the mechanism of dopamine-induced Ca2+ signal
generation we tested specific inhibitors of GPCR signal trans-
duction. The dopamine-induced Ca2+ signal is blocked by:
pertussis toxin (PTX), an inhibitor of Gai signaling (Figure 3E);
the PLC inhibitor (U73122) (Figure 3F); 2-aminoethoxydiphenyl
borate (2-APB) an antagonist of intracellular IP3 receptors (Fig-
ure 3G); thapsigargin (TG), a depletor of intracellular calcium
stores (Figure 3H). Hence, GHSR1a and DRD2 coexpression
results in dopamine-induced coupling to Gai, activation of
PLC, and production of IP3 that acts on IP3 receptors to release
Ca2+ from the endoplasmic reticulum.
Since dopamine-induced Ca2+ release is blocked by PTX
(Figure 3E), we reasoned the mechanism might involve direct
stimulation of PLC by Gbg subunits derived from Gai/o and
direct association of Gbg with GRK2 (Inglese et al., 1994; Koch
et al., 1994). To test for a role of GRK2, we expressed wild-
type GRK2 or a mutant GRK2 (GRK2-K220R) lacking kinase
activity in cells coexpressing GHSR1a and DRD2 (Namkung
and Sibley, 2004). Both WT and mutant GRK2 inhibit
dopamine-induced increases in Ca2+ (Figure 3I, p < 0.001).
Expression of the Gbg scavenger, bARK1ct (Koch et al., 1994)
dose-dependently inhibits dopamine-induced Ca2+ mobilization
(Figure 3J). Pretreating cells expressing GHSR1a and DRD2 with
small molecule inhibitors (M119 and M158C) of Gbg subunit
signaling (Bonacci et al., 2006) attenuates dopamine-induced
modification of Ca2+ release, whereas the inactive control
compound (M119B) is ineffective (Figure 3K). Hence, GHSR1a
modification of dopamine-induced signal transduction is medi-
ated by Gbg subunits.
Dopamine-Induced Ca2+Mobilization Is Independent
of GHSR1a Basal Activity
When GHSR1a is expressed at high concentrations under heter-
ologous nonnative conditions, it exhibits basal activity. There-
fore, in all experiments we expressed GHSR1a at concentrations
commensurate with the low levels exhibited in vivo and under
these conditions GHSR1a does not exhibit detectable basal
activity; nevertheless, it was important to rigorously test the(F) Pretreatment with the phospholipase C (PLC) inhibitor (U73122, 10 mM) blocks
DRD2.
(G) In cells coexpressing GHSR1a and DRD2, the dopamine-induced (100 nM)
antagonist 2-aminoethoxydiphenyl borate (2-APB).
(H) Thapsigargin pretreatment (100 nM) blocks dopamine-induced (100 nM) Ca2
(I) Overexpression of GRK2 or the GRK2 phosphorylation mutant (GRK2-K220R)
Ca2+ mobilization.
(J) The Gbg scavenger (bARK1ct) dose-dependently decreases dopamine-induc
(K) Cells coexpressing GHSR1a + DRD2 pretreated with small molecule inhibitor
(M119B) for 5 min before dopamine treatment. M119B is ineffective in inhibiting do
dopamine.
The data represent the mean ± SEM for three independent experiments in duplic
untreated control.possibility that basal activity of GHSR1a might be responsible
for altering canonical DRD2 signaling by receptor crosstalk.
We coexpressed DRD2withWT-GHSR1a and with three point
mutants that exhibit equivalent basal activity to WT-GHSR1a
(S123A-GHSR1a and M213K-GHSR1a), or lack basal activity
(F279L-GHSR1a) altogether (Feighner et al., 1998; Holst et al.,
2007), but may not have the ability to support DRD2 signaling.
Although WT-GHSR1a and S123A-GHSR1a and M213K-
GHSR1a all have identical basal activity, of the three, only WT-
GHSR1a coexpression with DRD2 mobilizes Ca2+ in response
to dopamine (Figure 4A). By direct contrast, coexpression of
DRD2 with the basally inactive mutant produces a modest
increase in Ca2+ mobilization in response to dopamine (Fig-
ure 4A). These results illustrate a lack of correlation between
dopamine-induced release of intracellular Ca2+ and GHSR1a
basal activity and are consistent with allosteric interactions
between GHSR1a and DRD2.
Agonist activation of GHSR1a in HEK293 cells results in
coupling to Gaq (Smith et al., 1997). Therefore, if modification
of DRD2 signaling by GHSR1a is caused by GHSR1a basal
activity, ablating Gaq expression should block DRD2-mediated
mobilization of Ca2+ by dopamine. When Gaq siRNA is ex-
pressed with GHSR1a and DRD2 dopamine-induced Ca2+
signaling is not suppressed (Figure 4B, left panel), whereas ghre-
lin-induced Ca2+ release is significantly reduced (Figure 4B, right
panel). To ensure that ablating Gaq suppresses GHSR1a basal
activity, we deliberately overexpressed GHSR1a to produce
detectable basal activity as measured by IP1 production. Coex-
pression of Gaq siRNA, but not control siRNA, suppresses IP1
production to control levels (Figure S2A). Also, overexpression
of Gaq protein does not increase dopamine-induced Ca
2+ mobi-
lization (Figure S2B). The PKC inhibitor, BisI, also does not
reduce dopamine-induced Ca2+ mobilization (Figure S2C).
These data provide evidence thatmodification of DRD2 signaling
by GHSR1a is independent of GHSR1a basal signaling through
Gaq and PKC.
Functional crosstalk between receptors that depends on basal
activity of a Gaq-coupled receptor is indicated when acute pre-
activation (3 min) with an agonist of the basally active receptor
synergistically increases the agonist response of the protomer
partner (Rives et al., 2009). In the case of GHSR1a and DRD2,
preincubation with ghrelin for 3 min has no effect on the amount
of Ca2+ released in response to dopamine (Figure S2D). Like-
wise, if dopamine-induced Ca2+ production is explained by
potentiation of GHSR1a activity by DRD2, activation of DRD2dopamine-induced (100 nM) Ca2+ release in cells coexpressing GHSR1a and
Ca2+ signal is attenuated after pretreatment with the intracellular IP3 receptor
+ release in cells coexpressing GHSR1a and DRD2.
in cells coexpressing GHSR1a and DRD2 inhibit dopamine-induced (100 nM)
ed (100 nM) Ca2+ mobilization in cells coexpressing GHSR1a + DRD2.
s of Gbg subunit signaling (M119 and M158C) and inactive control compound
pamine-induced Ca2+ release whereas M119 and 158C inhibit the response to
ate for each concentration point. *p < 0.05, **p < 0.01, and ***p < 0.001 versus
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Figure 4. Dopamine-Induced Ca2+ Release Is Inde-
pendent of GHSR1a Constitutive Activity in Cells
Coexpressing GHSR1a and DRD2
(A) Coexpression of GHSR1a point mutants S123A and
M213K that exhibit identical constitutive activity to WT-
GHSR1a, and F297L which is devoid of constitutive
activity Cells coexpressing DRD2 with either S123A or
M213K fail to mobilize Ca2+ in response to dopamine,
whereas the GHSR1a F279L point mutant exhibits Ca2+
mobilization in response to dopamine;
(B) Knockdown of Gaq subunit by siRNA does not inhibit
dopamine-induced Ca2+ mobilization (left panel), whereas
ghrelin-induced Ca2+ mobilization (right panel) is signifi-
cantly impaired.
The data represent the mean ± SEM for three independent
experiments in duplicate for each concentration point.
**p < 0.01 versus untreated control.
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Ca2+ mobilization. However, this is not the case; simultaneous
addition of ghrelin and dopamine results in additive Ca2+ accu-
mulation (Figures S2E and S2F).
Our collective results argue that dopamine-induced Ca2+
release is independent of GHSR1a basal activity and crosstalk
between signal transduction pathways. An alternative mecha-
nism is that GHSR1a-induced modification of canonical dopa-
mine-DRD2 signal transduction is a consequence of allosteric
modification of DRD2 signal transduction caused by formation
of GHSR1a:DRD2 heteromers.
Cross-Desensitization of GHSR1a and Dopamine
Receptors
Cross-desensitization caused by extended (30 min) preincuba-
tion of receptors with the agonist of one protomer would be
indirect evidence for possible formation of GHSR1a:DRD2
heteromers. Pretreatment of cells coexpressing GHSR1a and
DRD2 for 30 min with increasing concentrations of the GHSR1a
agonists MK-677 (Patchett et al., 1995) or ghrelin reduces dopa-
mine-induced Ca2+ mobilization by 60%–75% of the control
response (Figure 5A). MK-677 with a longer half-life than ghrelin
is significantly more efficient than ghrelin in attenuating DRD2-
induced Ca2+ signaling (MK-677 EC50 = 0.064 ± 0.0005 nM,
ghrelin EC50 = 0.87 ± 0.019 nM; p < 0.05; Figure 5A). Similarly,
preincubation with dopamine or quinpirole reduces ghrelin-
induced Ca2+ release by 60% and 50%, respectively (Figure 5B),
but preincubation with the D1R-selective agonist SKF81297
fails to inhibit the ghrelin-induced response (Figure 5B). Cross-
desensitization observed with a GHSR1a agonist or DRD2
agonist is consistent with a mechanism involving formation of
GHSR1a:DRD2.322 Neuron 73, 317–332, January 26, 2012 ª2012 Elsevier Inc.Heteromer Formation between GHSR1a
and DRD2
We employed time-resolved (Tr)-FRET to test
for heteromer formation because this tech-
nology is ideal for monitoring cell surface
protein-protein interactions at physiological
concentrations of receptors (Maurel et al.,
2008). We introduced a SNAP-tag at theGHSR1a N terminus and showed its appropriate expression on
the cell surface and its functional activity (Figures S3A and
S3B). Specific labeling of SNAP-GHSR1a was demonstrated
by SDS-PAGE in-gel fluorescence, fluorescent confocal micros-
copy, and dose-dependent cell surface labeling with BG-488
(Figures S3C–S3E).
To optimize the Tr-FRET signal, cells expressing SNAP-
GHSR1a were incubated with a fixed concentration of energy
donor (terbium cryptate, 100 nM) and increasing concentrations
of acceptor (Figure S3F) and a linear relationship between
receptor concentration and Tr-FRET signal was established
(Figure S3G). When GHSR1a is expressed alone, it forms homo-
mers and, consistent with formation of GHSR1a homomers, the
Tr-FRET signal is reduced according to the ratio SNAP-GHSR1a
to GHSR1a such that at a ratio of 1:1 Tr-FRET is reduced to
59% ± 6% and to 17% ± 3.7% at a 1:5 ratio (Figure 6A). When
DRD2 is substituted for GHSR1a, the Tr-FRET signal generated
by GHSR1a:GHSR1a homomers is reduced to 62% ± 10% by
a 1:1 ratio of GHSR1a to DRD2 (p < 0.01), and 36.6% ± 6.5%
by a 1:5 ratio, consistent with formation of GHSR1a:DRD2
heteromers (Figure 6A). When a control GPCR, RXFP1, is coex-
pressed with SNAP-GHSR1a, the Tr-FRET is not attenuated
(Figure 6A).
To confirm GHSR1a:DRD2 formation, we prepared CLIP-
tagged GHSR1a and SNAP-tagged DRD2 and examined
expression of these receptors by confocal microscopy. Both
the CLIP- and SNAP-tagged receptors are colocalized on the
cell surface (Figure 6B). We then conducted saturation assays
observing robust saturable Tr-FRET signals indicative of specific
heteromerization rather than random collisions (Figure 6C).
As a further test of heteromerization of GHSR1a and DRD2 we
utilized a SNAP-tagged DRD2 variant. We first defined
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Figure 5. Pretreatment of Cells Coexpressing GHSR1a and DRD2
with GHSR1a or DRD2 Agonists Results in Cross-Desensitization
of Agonist Signaling
(A) Aequorin-HEK293 cells coexpressing GHSR1a + DRD2 pretreated with
increasing concentrations of ghrelin (-) or MK-677 (:) for 30 min show
attenuated response to dopamine-induced (100 nM) Ca2+ mobilization.
(B) Aequorin-HEK293 cells coexpressing GHSR1a + DRD2 were pretreated
with increasing concentrations of dopamine (-), SKF81297 (:), or quinpirole
(;) for 30 min and Ca2+ mobilization measured after ghrelin treatment
(100 nM).
The data represent the mean ± SEM for three independent experiments in
duplicate for each concentration point.
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either fluorophore to detect homomers and tested for a linear
relationship between receptor DNA transfected and Tr-FRET
signal (Figures S4A and S4B). In Tr-FRET competition assays
with SNAP-DRD2, the Tr-FRET signal in the presence of
GHSR1a at a 1:1 ratio is significantly reduced compared to
empty vector (55.5% ± 13%, p < 0.05), and at a 1:5 ratio
further reduced (27.3% ± 6.5%, p < 0.01), consistent with heter-
omerization between GHSR1a and DRD2 (Figure 6D). Over a
range of receptor concentrations, high FRET signals are de-
tected in cells expressing SNAP-GHSR1a and CLIP-DRD2,
and in cells expressing SNAP-GHSR1a and CLIP-GHSR1a,
which is again consistent with GHSR1a and DRD2 heteromeriza-
tion (Figure 6E).
The results of Tr-FRET were compared to the magnitude of
dopamine-induced Ca2+ mobilization. In cells coexpressing
different ratios of GHSR1a to DRD2, dopamine-induced Ca2+
mobilization is highest in cells transfected with a 1:5 ratio of
GHSR1a to DRD2 (150%± 1.5%), compared to cells transfected
with a 1:1 ratio (Figure 6F, p < 0.001). Thus, the magnitude ofdopamine-induced Ca2+ release correlates with the level of
GHSR1a:DRD2 heteromers (Figure 6E).
Heteromerization and Conformation-Dependent
Functional Interaction between GHSR1a and DRD2
If modification of DRD2 signaling is a consequence of physical
association between the two receptors, it should be dependent
upon GHSR1a conformation. To test for dependence on confir-
mation WT-GHSR1a, M213K-GHSR1a and F279L-GHSR1a
that are equivalently expressed on the cell surface of HEK293
cells were employed (Figure S5A). Tr-FRET signals were
measured in cells coexpressing varying levels of CLIP-WT-
GHSR1a, CLIP-M213K-GHSR1a, and CLIP-F279L-GHSR1a
with a fixed concentration of SNAP-DRD2. The slope of the
relationship between cell surface expression and FRET signal
is significantly reduced (p < 0.05) with the M213K mutant
(slope = 0.06 ± 0.048) and F279L mutant (slope = 0.43 ± 0.06)
compared to WT-GHSR1a (slope = 1.11 ± 0.05), suggesting
that M213K and F279L less readily form heteromers with
DRD2 (Figure 7A).
To determine whether the reduced FRET signals in the case of
the point mutants might be explained by reduced efficiency, we
performed Tr-FRET acceptor titration assays in cells coexpress-
ing fixed amounts of SNAP-WT-GHSR1a and CLIP-DRD2,
SNAP-M213K-GHSR1a and CLIP-DRD2, or SNAP-F279L-
GHSR1a and CLIP-DRD2. A significant decrease (p < 0.05) in
FRET potency occurs in cells coexpressing M213K-GHSR1a
with DRD2 (FRET50 = 0.79 ± 0.22) and F279L-GHSR1a with
DRD2 (FRET50 = 0.49 ± 0.15), compared to WT-GHSR1a and
DRD2 (FRET50 = 0.086 ± 0.029). These results are consistent
with a reduced capacity of the M213K and F279L point mutants
to form heteromers with DRD2 (Figure 7B), suggesting that
a specific GHSR1a conformation is preferred for formation of
heteromers with DRD2. Since the M213K and F279L mutants
exhibit reduced capacity for dopamine-induced Ca2+ release
(Figure 4A), these results illustrate a positive correlation between
GHSR1a conformation and dopamine-induced Ca2+ signaling.
A more subtle way to alter confirmation and test for a mecha-
nism involving allosteric effects caused by heteromerization is
to use inverse agonists and antagonist selective for each proto-
mer. We tested the effects of the GHSR1a antagonist/inverse
agonist (L-765,867 aka Subst. P derivative) and the highly selec-
tive neutral antagonist JMV2959 on dopamine-induced Ca2+
signaling. Both compounds exhibit dose-dependent inhibition
of dopamine-induced Ca2+ signaling (Figure 7C). As predicted,
dopamine-induced Ca2+ release is dose-dependently inhibited
by the DRD2 antagonist raclopride and the inverse agonist
sulpiride (Figure 7D); however, sulpiride although not raclopride,
partially inhibited ghrelin-induced Ca2+ mobilization. Therefore,
in this context the DRD2 inverse agonist acts as a partial
GHSR1a antagonist (IC50 = 0.7 ± 0.02 mM, Figure 7E). These
compounds do not interfere with GHSR1a:DRD2 heteromeriza-
tion (data not shown) and these data are consistent with altered
conformation of protomers by their respective inverse agonist or
neutral antagonist as reflected by modification of signaling of
the protomer partner; furthermore, the results support a model
where allosteric modification of DRD2 signaling by GHSR1a is
dependent upon formation of heteromers.Neuron 73, 317–332, January 26, 2012 ª2012 Elsevier Inc. 323
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Figure 6. Detection of Heteromer Formation between GHSR1a and DRD2 In Vitro by Tr-FRET
(A) Tr-FRET competition assays where cells were transfected with increasing ratios of SNAP-GHSR1a and untagged GHSR1a, untagged DRD2 or an untagged
RXFP1.
(B) Cells cotransfected with CLIP- or SNAP-tagged receptor variants, labeled specifically with either green (BC-488, 2 mM) or red fluorophore (BG-647, 2 mM) and
then examined by confocal microscopy. Overlay pictures show colocalization of GHSR1a with DRD2.
(C) FRET acceptor saturation assays performed using constant amount of donor fluorophore (BG-TbK, 100 nM) and increasing amounts of acceptor fluorophore
(BC-647) in cells coexpressing SNAP- and CLIP-tagged receptor variants.
(D) GHSR1a:DRD2 formation measured by Tr-FRET competition assays; Tr-FRET measurements on cells transfected with SNAP-DRD2 in the presence of
different ratios of untagged GHSR1a.
(E) Homomerization of GHSR1a and heteromerization of GHSR1a and DRD2 by Tr-FRET receptor titration. Cells were cotransfected with constant amount of
SNAP-GHSR1a and increasing amounts of HA-CLIP-GHSR1a or HA-CLIP-DRD2. The HA-tagged receptor cell surface expression was determined by cell
surface ELISA and Tr-FRET signal plotted as a function of cell surface expressed HA-CLIP-tagged receptor.
(F) Magnitude of dopamine-induced Ca2+ release is dependent on formation of GHSR1a:DRD2 heteromers; intracellular Ca2+ mobilization induced by dopamine
(10 mM) in aequorin HEK293 cells expressing different ratios of GHSR1a to DRD2.
The data represent the mean ± SEM for three independent experiments in duplicate for each concentration point. **p < 0.01, ***p < 0.001 versus control.
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Heteromers of GHSR1a and DRD2 Relevant in FeedingDetection of GHSR1a and DRD2 Heteromers in Native
Tissues
We next directly addressed the question of whether
GHSR1a:DRD2 heteromers exist in the brain by using fluores-324 Neuron 73, 317–332, January 26, 2012 ª2012 Elsevier Inc.cently labeled ghrelin (red-ghrelin) to localize GHSR1a expres-
sion. First our approach employing red-ghrelin was validated.
In HEK293 cells expressing SNAP-GHSR1a a robust FRET signal
was generated following binding of red ghrelin (Kd = 28 nM;
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Figure 7. GHSR1a Point Mutants Illustrate GHSR1a:DRD2 Formation Is Dependent on GHSR1a Structure
Tr-FRET experiments comparing heteromerization of wild-type GHSR1a, M213K-GHSR1a, and F279L-GHSR1a point mutants in the presence of DRD2.
(A) Tr-FRET receptor titration assays were performed to assess heteromerization. Cells were cotransfected with increasing amounts of HA-CLIP-tagged
receptors; the FRET signal is represented as a function of cell surface expression of HA-tagged receptors.
(B) Tr-FRET acceptor titration assay to determine heteromer formation. FRET intensity signals were measured in cells coexpressing CLIP-tagged WT-GHSR1a,
M213K or F279L point mutants in the presence of SNAP-DRD2 and labeled with constant amount of donor (BG-TbK, 100 nM) and increasing amount of acceptor
fluorophore (BC-647).
(C) Dose-dependent inhibition of dopamine-inducedmobilization of [Ca2+]i in cells coexpressing GHSR1a + DRD2 by GHSR1a neutral antagonists JMV2959 and
substance P derivative.
(D) Dose-dependent inhibition of dopamine-induced (10 mM) Ca2+ mobilization by DRD2 antagonist (raclopride,-) and inverse agonist (sulpiride, :) in cells
coexpressing GHSR1a + DRD2.
(E) Sulpiride (-) but not raclopride (:) inhibits ghrelin-induced (100 nM) Ca2+ mobilization in cells coexpressing GHSR1a+DRD2.
The data represent the mean ± SEM for three independent experiments in duplicate for each concentration point.
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Heteromers of GHSR1a and DRD2 Relevant in FeedingFigure S6A). Illustrating red ghrelin specificity, unlabeled ghrelin
and the highly selective GHSR1a agonist, MK-677 (Patchett
et al., 1995) competitively inhibit red ghrelin binding (IC50 =
215 ± 30 nM and 35 ± 20 nM, respectively), but des-acyl ghrelin
was ineffective (Figure S6B). In brain slices from ghsr +/+ mouse,
but not in slices from ghsr/ mouse, red ghrelin is observed
confirming the specificity of fluorescent red-ghrelin binding to
GHSR1a (Figure S6C).
Red ghrelin was next used to test for formation of
GHSR1a:DRD2 heteromers in vitro. SNAP-tagged receptors
labeled with cryptate fluorophore donor produces dose-depen-dent increases in FRET in cells coexpressing SNAP-GHSR1a
and GHSR1a or SNAP-DRD2 and GHSR1a in the presence of
red-ghrelin (Figure S6D.). When different ratios of GHSR1a and
SNAP-DRD2 (1:1 and 1:2) are expressed, the FRET signals asso-
ciated with red-ghrelin correlate with the relative ratios of
GHSR1a to DRD2 (Figure S6E), consistent with GHSR1a and
DRD2-specific heteromerization.
Next, we performed the red-ghrelin Tr-FRET assay on tissue
isolated from different regions of mouse brain. Membrane
preparations from striatum and hypothalamus were incubated
with red-ghrelin (acceptor fluorophore), a specific antibody forNeuron 73, 317–332, January 26, 2012 ª2012 Elsevier Inc. 325
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Figure 8. Detection GHSR1a:DRD2 Heteromers In Vivo by Tr-FRET and the Dependence of the Anorexigenic Effect of a DRD2 Agonist on
GHSR1a
(A) Tr-FRET signal detection onmembrane preparations from striatum and hypothalamus after labeling with red-ghrelin (100 nM, acceptor fluorophore), antibody
for DRD2 and cryptate labeled secondary antibody (10 nM, donor fluorophore). Nonspecific FRET signal wasmeasured onmembranes in the presence 100 nM of
red-fluorophore, antibody for DRD2and cryptate labeled secondary antibody (10 nM, donor fluorophore). The data represent the mean ± SEM for three inde-
pendent experiments in duplicate for each point. ns, not significant;*p < 0.05 versus control.
(B) Tr-FRET signals detected on membrane preparations of striatum and hypothalamus from ghsr+/+ and ghsr/mice. Membranes were labeled in the presence
of 100 nM red-ghrelin (acceptor), antibody for DRD2 and 10 nM cryptate labeled secondary antibody (donor). The data represent the mean ± SEM for three
independent experiments in duplicate for each point. ns, not significant;*p < 0.05 versus control.
(C) Confocal microscope FRET analysis of GHSR1a:DRD2 heteromer formation in gsr+/+mouse hypothalamic (upper panels) striatal (middle panels) neurons and
ghsr/mouse hypothalamic neurons (lower panels). Brain slices were stained with 100 nM red-ghrelin (acceptor), DRD2 antibody, and Cy3-labeled secondary
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Heteromers of GHSR1a and DRD2 Relevant in FeedingDRD2 and cryptate labeled secondary antibody (donor fluoro-
phore). Although membranes from the striatum exhibit a slightly
higher FRET signal, the increase does not reach significance
(Figure 8A). In hypothalamic membrane preparations, a signifi-
cantly higher FRET signal is observed (198 ± 27, compared to
background, 100 ± 5.7, p < 0.05; Figure 8A) in agreement with
relative levels of receptor mRNA (Figure 1). To test specificity,
we repeated the Tr-FRET assays on membrane preparations of
brain tissues from ghsr+/+ and ghsr/ mice in parallel. Signifi-
cantly higher FRET signals are observed in hypothalamus from
ghsr+/+ mice compared to ghsr/ mice (p < 0.05; Figure 8B),
illustrating the specificity of the Tr-FRET signal in the hypothal-
amus of wild-type mice. Again, Tr-FRET signals in the striatum
did not reach statistical significance (Figure 8B).
We then tested for GHSR1a:DRD2 heteromers in brain slices
from ghsr+/+ and ghsr/ mice. In the hypothalamus of ghsr+/+,
but not ghsr/, mice, confocal FRET analysis shows that
GHSR1a andDRD2 are in close proximity with a relative distance
of 5–6 nm (50–60 A˚) and FRET intensity ranging from 0.4 to 0.6
(Figure 8C). In the striatum, FRET intensity signals are very
weak (Figure 8C). To summarize, Tr-FRET analysis of membrane
preparations and FRET analysis from single neurons by confocal
microscopy confirm heteromer formation between natively ex-
pressed GHSR1a and DRD2 in the hypothalamus of wild-type
mice.
Physiological Relevance of GHSR1a Interactions
with DRD2
The in vivo detection of GHSR1a:DRD2 heteromers and in vitro
cell-based data led us to ask whether preventing formation of
GHSR1a:DRD2 heteromers would be associated with an altered
behavioral phenotype. DRD2 activation suppresses appetite
(Comings et al., 1996; Epstein et al., 2007; Stice et al., 2008). In
cells coexpressing GHSR1a and DRD2 the DRD2 selective
agonist cabergoline induces a dose-dependent mobilization of
Ca2+ (Figure S7A), and treating mice with cabergoline (0.5 and
2 mg/kg) results in dose-dependent suppression of food intake
(Figure S7B); therefore, to test whether cabergoline’s effect was
dependent upon GHSR1a and DRD2 interactions, we compared
food intake in ghsr+/+ and ghsr/ treated with cabergoline. In
ghsr+/+mice, food intake ismarkedly reducedwithin2hr of caber-
goline treatment compared to vehicle-treated mice (p < 0.05;
Figure 8D, left graph), whereas food intake in ghsr/ mice is
unaffected by cabergoline treatment (Figure 8D, right graph).antibody (donor). Red color indicates GHSR1a staining, green DRD2 localizatio
receptors and colocalization of two receptors (overlay).
(D) Effect of cabergoline administration on food intake in ghsr+/+ mice (n = 4 fo
cabergoline and n = 5 for vehicle; right graph). Mice were injected i.p. with cabe
(vehicle). Food intake wasmeasured at 1, 2, 4, 6, 20, and 24 hr after injections. Ave
**p < 0.01 versus control vehicle treatments. The data represent the mean ± SEM
(E) The neutral GHSR1a selective antagonist JMV2959 antagonizes cabergoline-i
for vehicle; left graph) and had no effect in ghsr/mice (n = 5 for cabergoline and
dose, 30min before cabergoline treatments (0.5 mg/kg). Food intake wasmeasur
for each time point.
(F) Effect of cabergoline administration on food intake in ghrelin+/+ mice (n = 6 fo
cabergoline and n = 5 for vehicle, right graph). Mice were injected i.p. with cabe
(vehicle). Food intakewasmeasured at 1, 2, 4, 6, 20, and 24 hr after injections. *p <
each time point.In cells coexpressing GHSR1a andDRD2, the GHSR1a neutral
antagonist, JMV2959 (Moulin et al., 2007) attenuates dopamine-
induced Ca2+ mobilization (Figure 7C). To test if inhibition of
DRD2 signaling by JMV2959 in cells would translate to the
whole animal we treated wild-type mice with JMV2959 prior to
cabergoline treatment. Indeed, cabergoline-induced suppres-
sion of food intake in ghsr+/+ mice was prevented by pretreat-
ment with JMV2959 (0.2 mg/kg, Figure 8E, left graph), whereas
food intake in cabergoline-treated ghsr/ mice was unaffected
by JMV2959 treatment (Figure 8E, right graph).
In cell-based assays, we showed that GHSR1amodifies DRD2
signaling in the absence of ghrelin. Because both ghsr+/+ and
ghsr/ produce endogenous ghrelin, to test for a possible role
of endogenous ghrelin on DRD2 signaling in vivo, we compared
the effects of cabergoline treatment on food intake in ghrelin/
and ghrelin+/+ mice. Cabergoline (0.5 mg/kg) significantly
reduced food intake irrespective of genotype (Figure 8F). Hence,
antagonism of the anorexigenic effect of cabergoline by
JMV2959 (Figure 8E) is not dependent on endogenous ghrelin
but on the presence of GHSR1a, illustrating the physiological
relevance of interactions between GHSR1a and DRD2 on dopa-
mine signaling.
DISCUSSION
We investigated the interaction of the GHSR1a and DRD2
signaling systems and found molecular, cellular, and physiolog-
ical bases for functional and structural interactions in vivo and
in vitro. Here, we show that in mouse hypothalamic neurons
coexpressing GHSR1a and DRD2 heteromers are formed.
Heteromerization of GPCRs is an important mechanism that
can regulate receptor function. Receptor-receptor interactions
potentially stabilize specific conformations and lead to coupling
with discrete effectors resulting in heteromer-specific signal
transduction. Here, we found that dopamine or a selective
DRD2 agonist activates GHSR1a:DRD2 heteromers inducing
Gbg and PLC-dependent mobilization of Ca2+ from intracellular
stores. Most importantly, this modification of DRD2 signaling is
observed in the absence of ghrelin, showing that apo-GHSR1a
behaves as an allosteric modulator of dopamine-DRD2 sig-
naling. This finding resolves the paradox and documents a
function for GHSR1a expressed in areas of the brain considered
inaccessible to peripherally produced ghrelin and where there is
no evidence of ghrelin production.n. Microscopic analysis shows FRET intensity, distances separating the two
r cabergoline and n = 4 for vehicle; left graph) and in ghsr/ mice (n = 5 for
rgoline (0.5 mg/kg) in 100 ml of physiological saline or with 100 ml saline alone
rage body weight mass of ghsr+/+ was 31.8 g and ghsr/was 28.1 g; *p < 0.05,
for each time point.
nduced reduction on food intake in ghsr+/+mice (n = 4 for cabergoline and n = 4
n = 5 for vehicle; right graph). Mice were injected i.p. with JMV295 at 0.2 mg/kg
ed at 1, 2, 4, 6, 20, and 24 hr after injection. The data represent the mean ± SEM
r cabergoline and n = 4 for vehicle, left graph) and in ghrelin/ mice (n = 5 for
rgoline (0.5 mg/kg) in 100 ml of physiological saline or with 100 ml saline alone
0.05 versus control vehicle treatments. The data represent themean ± SEM for
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identified in ghsr-IRES-tauGFP mice by a combination of GFP
and DRD2 immunohistochemistry. Colocalization is most abun-
dant in hypothalamic neurons, consistent with results of in situ
hybridization (Guan et al., 1997) and RT-PCR. We asked what
effects coexpression of GHSR1a and DRD2 would have on
dopamine signal transduction in these neurons. Using HEK293
cells, SH-SY5Y, GHSR-SH-SY5Y, and primary cultures of hypo-
thalamic neurons we showed that coexpression of GHSR1a and
DRD2 altered canonical DRD2 signal transduction resulting in
dopamine-induced mobilization of [Ca2+]i. In this context mobili-
zation of [Ca2+]i by dopamine is dependent upon Gbg subunit
activation of PLC and inositol phosphate pathways.
GHSR1a is present at extraordinary low levels in native tissues
(Howard et al., 1996). A widely held belief, based on the basal
activity exhibited by GHSR1a when expressed in heterologous
systems at higher levels than in native tissues, is that GHSR1a
basal activity is physiologically relevant. Although we do not
share this belief, it was incumbent upon us to test whether
GHSR1a basal activity might explain the effects of GHSR1a on
modification of canonical DRD2 signaling. Perhaps, the most
relevant example of basal activity of one GPCR modifying
signaling of another by receptor crosstalk is coexpression of
mGlu1a with GABAB receptor (Rives et al., 2009). In common
with GHSR1a, mGlu1a couples to Gaq, and like DRD2, GABAB
couples to Gai/o. Coexpression of these receptors produces
a synergistic increase in GABA-induced mobilization of [Ca2+]i.
The authors concluded that potentiation of [Ca2+]i mobilization
was a consequence of temporal integration of [Ca2+]i responses
as a result of mGlu1a basal activity. However, in the context
of GHSR1a and DRD2 coexpression we found no evidence
of receptor crosstalk producing augmentation of [Ca2+]i in
response to agonists of either receptor.
It is well known that expression of GHSR1a in cell lines at
levels exceeding those observed in native tissues is accompa-
nied by detectable basal activity. Therefore, in our studies we
deliberately used low-level GHSR1a expression commensurate
with what is observed in native tissues. However, a case for
a physiological role for GHSR1a basal activity was concluded
from experiments showing inhibition of feeding in rats during
a 6 day central infusion of the GHSR1a inverse agonist,
[D-Arg1,D-Phe5,D-Trp7,9,Leu11]-substance P (Petersen et al.,
2009). Although modest reductions in food intake and weight
gain were observed, the results are ambiguous because the
study was compromised by side effects observed following
cannulation and implantation of infusion pumps. Furthermore,
this inverse agonist is not highly selective. Nevertheless, based
on this report it was incumbent on us to rigorously test whether
basal activity of GHSR1a explained modification of canonical
DRD2 signaling.
We selected point mutants of GHSR1a described as exhibiting
the same basal activity as WT-GHSR1a, and a mutant devoid of
basal activity to test for correlation with modification of DRD2
signal transduction. There was no correlation between basal
activity of the mutants and dopamine-induced mobilization of
[Ca2+]i. GHSR1a couples to Gaq (Howard et al., 1996); therefore,
to eliminate possible basal activity we suppressed Gaq produc-
tion by expressingGaq siRNA in cells coexpressingGHSR1a and328 Neuron 73, 317–332, January 26, 2012 ª2012 Elsevier Inc.DRD2. Dopamine-inducedmobilization of [Ca2+]i was unaffected
by inhibition of Gaq expression. Furthermore, inhibition of PKC
signaling blocks GHSR1a signal transduction (Smith et al.,
1997), but we show PKC inhibition does not inhibit dopamine-
induced mobilization of [Ca2+]i. Collectively, these results
preclude basal activity of GHSR1a as an explanation for modifi-
cation of DRD2 signal transduction.
Our results are consistent with an allosteric mechanism
associated with physical association between GHSR1a and
DRD2. Indeed, the results of agonist cross-desensitization
assays support this mechanism. GPCRs are known to form
homo- and heteromers in vitro and these complexes can
modulate receptor signaling and trafficking (Bulenger et al.,
2005; Milligan, 2009; Terrillon and Bouvier, 2004). Although
dimerization in vitro is well documented, its physiological rele-
vance has been questioned because of the paucity of reports
showing theexistenceofGPCRdimers in native tissue.Neverthe-
less, the functional requirement for dimerization in the case of the
GABAB receptor is undeniable (Jones et al., 1998). We employed
Tr-FRET methodology to test for formation of GHSR1a:DRD2
heteromers because its high sensitivity and high signal-to-noise
ratio is ideal for detecting homo- and heteromers on cell surfaces
at physiological levels of GPCR expression (Maurel et al., 2008;
Albizu et al., 2010). Tr-FRET assays using SNAP- and CLIP-
tagged GHSR1a and DRD2 showed heteromers formed at equi-
molar concentrations of GHSR1a and DRD2. By comparing
Tr-FRET signals obtained from combinations of SNAP- and
CLIP-tagged DRD2, SNAP-, and CLIP-tagged WT-GHSR1a
and GHSR1a point mutants with associated dopamine-induced
mobilization of Ca2+, we concluded that function correlates with
the Tr-FRET signal produced by GHSR1a:DRD2 heteromers.
The results of experiments with DRD2 and GHSR1a point
mutants illustrate that heteromer formation is dependent upon
GHSR1a conformation. However, to support a mechanism of
allosteric modulation more subtle changes that do not cause
dissociation of the heteromers must be induced. Conformation
and dimerization of GPCRs is affected by inverse agonists and
antagonists (Fung et al., 2009; Guo et al., 2005; Mancia et al.,
2008; Vilardaga et al., 2008). A neutral antagonist or inverse
agonist of one protomer can modify function of the other proto-
mer via allostery (Smith and Milligan, 2010). In the case of CB1R
and m-opioid receptor where integration of signaling occurs
through crosstalk mediated by basal activity, an inverse agonist,
but not a neutral antagonist reduced activity (Canals and
Milligan, 2008). In contrast, the GHSR1a neutral antagonist
JMV2959 (Moulin et al., 2007), inhibits dopamine-induced Ca2+
release consistent with an allosteric effect associated with
GHSR1a:DRD2 heteromers. With DRD2 homomers, binding of
the inverse agonist (sulpiride) to one protomer modifies the
signal generated by the other (Han et al., 2009). Likewise, sulpir-
ide modifies ghrelin-induced Ca2+ release by GHSR1a:DRD2
heteromers consistent with allosteric modification of signaling
between the protomers.
To test for endogenously formed GHSR1a:DRD2 heteromers
in native tissue, we performed Tr-FRET assays on hypothalamic
and striatal membrane preparations isolated from ghsr+/+ and
ghsr/ mouse brains. The highest FRET signals were observed
in hypothalamic membranes from ghsr+/+ mice, illustrating
Neuron
Heteromers of GHSR1a and DRD2 Relevant in FeedingGHSR1a:DRD2 heteromer formation. As confirmation we per-
formed confocal microscope FRET analysis on brain slices
from ghsr+/+ and ghsr/mice. The robust FRET signals in hypo-
thalamic neurons of ghsr+/+ but not ghsr/ mice show the exis-
tence of GHSR1a:DRD2 heteromers in native hypothalamic
neurons.
It was important to determine whether interaction between
GHSR1a and DRD2 was associated with a DRD2 dependent
behavioral phenotype. For these experiments, we selected the
DRD2 agonist cabergoline. Cabergoline is widely used clinically
for treatment of Parkinson disease and hyperprolactinemia and
has greater selectivity for DRD2 compared to other dopamine
and serotonin receptor subtypes (Kvernmo et al., 2006). Besides
other pathways, DRD2 regulates feeding behavior (Fetissov
et al., 2002; Palmiter, 2007), and humans treated with cabergo-
line experience weight loss (Korner et al., 2003). Because the
hypothalamus is a key regulatory center for food intake, we
hypothesized that cabergoline acts on these neurons to induce
anorexia. Pharmacological doses of ghrelin increase food intake,
therefore, it is possible that cabergoline inhibits food intake by
lowering endogenous ghrelin concentrations, or by interfering
with ghrelin signaling. Alternatively, cabergoline suppression of
feeding may require the allosteric effect of GHSR1a on DRD2
signaling. To test these possibilities, we compared food intake
in ghsr+/+ mice and ghsr/ mice treated with cabergoline. If
cabergoline interfered with endogenous ghrelin signaling, food
intake should be inhibited in both genotypes and perhaps exag-
gerated in ghsr/mice; however, ghsr/mice were completely
refractory to cabergoline-induced anorexia, illustrating depen-
dence on GHSR1a.
To test whether the allosteric interaction between DRD2 and
GHSR1a could be targeted pharmacologically, we treated
mice with the highly selective neutral GHSR1a antagonist
JMV2959 prior to cabergoline treatment. As predicted by our
hypothesis, JMV2959 blocked cabergoline-induced anorexia.
The demonstration that JMV2959 treatment of WT mice recapit-
ulates the phenotype observed in ghsr/ mice indicates that
resistance of ghsr/ mice to cabergoline is further evidence of
an allosteric function for GHSR1a on DRD2-mediated inhibition
of food intake. This result also argues against possible develop-
mental changes caused by ghsr ablation as an explanation of the
resistance of ghsr/ mice to cabergoline.
Although counter to evidence that ghrelin stimulates rather
than inhibits feeding behavior, the unlikely possibility remained
that blocking endogenous ghrelin signalingwith either aGHSR1a
antagonist or ablation of ghsr might overcome the inhibitory
effect of cabergoline on food intake. If this were true, then
ghrelin/ mice, like ghsr/ should be resistant to the anorexic
effect of cabergoline. When food intake was compared
in vehicle-treated and cabergoline-treated ghrelin+/+ and
ghrelin/ mice, suppression of food intake by cabergoline
was identical in both genotypes. These results provide additional
evidence that cabergoline-induced anorexia is dependent upon
allosteric interactions between GHSR1a and DRD2.
Our findings are of fundamental importance because they
support the notion that in subsets of neurons coexpressing
GHSR1a and DRD2 allosteric modulation by GHSR1a results in
a differential response to endogenous dopamine. Most impor-tantly, we show that a neutral GHSR1a antagonist blocks
dopamine signaling in neurons coexpressing DRD2 and
GHSR1a, which allows neuronal selective fine-tuning of dopa-
mine/DRD2 signaling because neurons expressing DRD2 alone
will be unaffected. This provides exciting opportunities for
designing the next generation of drugs with improved side effect
profile for treating psychiatric disorders associated with dysre-
gulation of dopamine signaling.
EXPERIMENTAL PROCEDURES
Small molecule molecule inhibitors of Gbg subunit signaling were obtained
from the chemical diversity set of the NCI/NIH Developmental Therapeutics
Program. M119 is referenced as compound NSC 119910, M119B is refer-
enced as compound NSC 119892 and M158C is referenced as compound
NSC 158110.
Animals
Ghsr+/+, ghsr/, ghrelin+/+, and ghrelin/ were backcrossed with C57BL/6J
mice for at least 15 generations (Sun et al., 2004). All studies were done in
accordance with protocols approved by the Institutional Animal Care and
Use Committee of Scripps Florida.
RT-PCR and Detection of mRNA Expression of ghsr1a and drd2 in
Mouse Brain
Tissue extractions for analysis of gene expression were carried out on adult
3-month-old mice. Mice were killed by decapitation after a brief exposure
to carbon dioxide brains were removed and immediately dissected using
a coronal brain matrix. Tissue homogenization, RNA isolation, cDNA template
preparation and sequence of primers can be found in Supplemental
Experimental Procedures.
Immunofluorescence Microscopy of Mouse Brain Sections
Immunofluorescence was carried out on adult male ghsr-IRES-tauGFP mice
as described previously (Jiang et al., 2006). Brains were quickly removed as
described above, snap frozen, and stored at 80C. Frozen brains were
embedded with Tissue-Tek (Sakura Finetek) and cut into 20 mm coronal
sections using Leica CM1950 cryostat (Leica Microsytems). Detailed protocol
for fixation and staining with primary and secondary antibodies of brain
sections can be found in Supplemental Experimental Procedures.
Plasmid Constructs
The N-terminally HA-tagged GHSR1a was generated by introducing HA
sequence into GHSR1a cDNA (Jiang et al., 2006) by PCR. The SNAP- and
CLIP-tag receptor variants were generated by PCR (for template cDNA,
SNAP- and CLIP-empty vectors were purchased from Cisbio US, Bedford,
MA) and subcloned into mammalian pcDNA3.1. The SNAP- and CLIP-
F279L-GHSR1a was constructed by subcloning point mutant F279L-GHSR1a
(Feighner et al., 1998) into SNAP- or CLIP-GHSR1a. The RXFP1 expression
vector was described previously (Kern et al., 2007). HA-tagged DRD2 and
Gaq expression vectors were purchased from Missouri cDNA Resource
Center (Rolla, MO). bARKct clone was the generous gift of Dr. R. Lefkowitz
(Duke University Medical Center, Durham, NC). The integrity of all constructs
generated by PCR and subcloning was confirmed by nucleotide sequencing.
Cell Culture, Plasmid, and siRNA Transfections
HEK293 (ATCC number: CRL-1573) and neuronal SH-SY5Y (ATCC number:
CRL-2266) cells were grown routinely in DMEM/F12 supplemented with
10% fetal bovine serum and 100 mg/ml of penicillin/streptomycin in a humidi-
fied atmosphere at 37C and 95% air/5% CO2. HEK293 cells stably express-
ing aequorin (HEK-AEQ) weremaintained in abovemedia containing 500 mg/ml
Geneticin (Invitrogen). Mouse hypothalamic tissue of embryonic day 18mouse
was purchased fromBrainBits (Springfield, IL), primary neurons were prepared
and the [Ca2+]i mobilization assay performed after cultivating neurons in
NbActiv4 neuronal culture medium (BrainBits). Detailed protocol for transientNeuron 73, 317–332, January 26, 2012 ª2012 Elsevier Inc. 329
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can be found in Supplemental Experimental Procedures.
Ca2+ Mobilization Assays
The aequorin bioluminescence assay was carried out as described previously
(Feighner et al., 1998; Howard et al., 1996) and live cell Ca2+ mobilization
assays in neuronal SH-SY5Y cells and primary hypothalamic neurons were
performed with the Fluo-4 direct assay (Invitrogen), see detailed protocols in
Supplemental Experimental Procedures.
Live Cell Time Resolved FRET
Labeling of cells was performed after 48 hr of transfection, as described
previously (Maurel et al., 2008). Cell labeling with terbium cryptate donor
and acceptor fluorophore, and time-resolved (Tr) FRET measurements were
performed as described in Supplemental Experimental Procedures.
Tr-FRET Binding Assays
Fluorescently-labeled ghrelin (red-ghrelin from Cisbio) binding assays were
performed on batch labeled cells with terbium-cryptate. Forty-eight hours after
transfection with SNAP-tagged receptors, cells were labeled with 100 nM of
BG-TbK (Cisbio) substrate in 6-well plates by incubating for 1 hr at 37C
(95% air/5% CO2) in DMEM containing 0.5% FBS. Cells were then detached,
collected by centrifugation (1,000 3 g, 10 min) and washed three times with
PBS. Pelleted cells were resuspended in Tris-KREBS buffer and seeded in
96-well plates (50 3 103 cells per well). Saturation binding, nonspecific
binding, and completion binding experiments were performed as described
in Supplemental Experimental Procedures.
Tr-FRET Assay on Membrane Preparations from Mouse Brain
Mouse brains were dissected as above and crude membrane preparations
were isolated, labeled with biotin, and added to streptavidin plates for labeling
with donor and acceptor fluorophores (see details in Supplemental Experi-
mental Procedures). Red-ghrelin (100 nM) and mouse anti-DRD2 antibody
(1:100 dilutions, Santa Cruz Biotechnology) were added and the plates incu-
bated overnight at 4C in the dark. To measure the background signal,
membranes were incubated with 100 nM of red-fluorophore and mouse
anti-DRD2 antibody. Plates were washed twice with TMEP and incubated
with terbium-kryptate labeled anti-mouse antibody (10 nM/well; Cisbio) for
2 hr at 4C in the dark. After two final washes, 400 mM KF in TMEP was added
to each well and Tr-FRET signal was measured using an EnVision plate reader
as described above.
FRET Microscopy on Brain Slices
Mouse brain sections (20 mm)were processed for FRET studies. Sections were
stained with red-ghrelin, primary mouse DRD2 antibody, secondary goat anti-
mouse Cy3 labeled antibody and FRET microscopy was performed using
Olympus FluoView 1000 (details in Supplemental Experimental Procedures).
Food-Intake Experiments
Age-matched WT, ghsr/, or ghrelin/ mice were housed individually for
1 week before food-intake measurements. Mice were kept in a standard 7
a.m. to 7 p.m. light cycle facility and fed with a regular mouse chow. Mice
were fasted for 16 hr before cabergoline and JMV2959 administration.
Cabergoline (Tocris) was dissolved in 0.9% saline (1 ml), acidified with 2%
of phosphoric acid (30 ml), and administered at 0.5 mg/kg doses. Either
cabergoline in 100 ml of 0.9% saline buffer or 100 ml of 0.9% saline was admin-
istered intraperitoneally. JMV2959 has been kindly provided by Aeterna
Zentaris GmbH, Frankfurt, Germany.As described previously, JMV2959 was
administered intraperitoneally (Moulin et al., 2007) at 0.2 mg/kg dose, 30 min
before cabergoline treatments. Food intake was measured at 1, 2, 4, 6, 20,
and 24 hr after injection.
Data Analysis
The mean and the SEM are presented for values obtained from the number of
separate experiments indicated, and comparisons were made using two-
tailed Student’s t test or one-way ANOVA test. Data were analyzed using330 Neuron 73, 317–332, January 26, 2012 ª2012 Elsevier Inc.GraphPad Instat Software and differences judged to be statistically significant
if p < 0.05.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and seven figures and can be found with this article online at doi:10.1016/j.
neuron.2011.10.038.
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